Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin and depression

H A Ring1, R Crellin, S Kirker

  • 1Department of Neurology, Maudsley Hospital, London.

Journal of Neurology, Neurosurgery, and Psychiatry
|August 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anglo-French neurological interactions in the 19th and early 20th centuries: Societies and Journals.

Revue neurologique·2022
Same author

Anglo-French neurological interactions in the 19th and early 20th centuries: Physicians, places and events.

Revue neurologique·2021
Same author

Allbutt of Leeds and Duchenne de Boulogne: Newly discovered insights on Duchenne by a British neuropsychiatrist.

Revue neurologique·2018
Same author

A brief history of hysteria: From the ancient to the modern.

Handbook of clinical neurology·2016
Same author

What is the safe upper intake level of folic acid for the nervous system? Implications for folic acid fortification policies.

European journal of clinical nutrition·2016
Same author

Novel insights into maladaptive behaviours in Prader-Willi syndrome: serendipitous findings from an open trial of vagus nerve stimulation.

Journal of intellectual disability research : JIDR·2015
Same journal

Diagnostic accuracy of a two-cut-off approach using the FAQ/MMSE ratio and FAQ for clinical preselection of patients for anti-amyloid therapy.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Cancer risk and mortality in patients with multiple sclerosis in Finland: a retrospective population-based cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Visuospatial working memory in Huntington's disease: behavioural and structural brain correlates.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Characteristics and outcomes in electric scooter-related traumatic brain injuries in Helsinki.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same journal

Durable fluoropolymer drug-eluting stent versus bare-metal stent for the prevention of intracranial in-stent restenosis.

Journal of neurology, neurosurgery, and psychiatry·2026
See all related articles

Vigabatrin, an epilepsy medication, may trigger major depressive episodes in patients, often early in treatment or after dose increases. These findings suggest a link between GABAergic mechanisms and mood disorders.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Intractable epilepsy requires effective treatment options.
  • Vigabatrin is an antiepileptic drug that modulates GABAergic neurotransmission.
  • Mood disorders are complex conditions with various contributing factors.

Observation:

  • Ten patients treated with vigabatrin for epilepsy developed major depressive episodes.
  • Depression onset typically occurred early in vigabatrin treatment or after dose escalation.
  • Symptoms appeared at daily doses ranging from 1.5 g to 4 g.

Findings:

  • Depressive symptoms in patients were associated with vigabatrin therapy.
  • A history of affective disturbance was noted in most affected patients.

Related Experiment Videos

  • The occurrence of depression was sometimes linked to reduced seizure frequency.

    • Implications:

    • GABAergic mechanisms may play a role in the pathophysiology of mood disorders.
    • Clinicians should monitor for depressive symptoms in patients taking vigabatrin.
    • Further research into the neurobiological underpinnings of vigabatrin-induced depression is warranted.